Showing results (291-300 of 637) with videos related to

Sort By:
Pageof 64
Studies in Health Technology and Informatics|August 8, 2025
VaxPulse: Active Global Vaccine Infodemic Risk AssessmentGerardo Luis Dimaguila, Muhammad Javed, Jeremiah Munakabayo, et al.
Studies in Health Technology and Informatics|August 8, 2025
Enhancing Vaccine Safety Surveillance: Extracting Vaccine Mentions from Emergency Department Triage Notes Using Fine-Tuned Large Language ModelsSedigh Khademi, Jim Black, Christopher Palmer, et al.
JMIR AI|August 30, 2024
Near Real-Time Syndromic Surveillance of Emergency Department Triage Texts Using Natural Language Processing: Case Study in Febrile Convulsion DetectionSedigh Khademi, Christopher Palmer, Muhammad Javed, et al.
The Medical Journal of Australia|April 1, 2011
Syncope and seizures following human papillomavirus vaccination: a retrospective case seriesNigel W Crawford, Hazel J Clothier, Sonja Elia, et al.
Journal of Paediatrics and Child Health|September 16, 2009
Immunisation practices in infants born prematurely: neonatologists' survey and clinical auditNigel W Crawford, Vivien Yeo, Rod W Hunt, et al.
Biochemical Pharmacology|November 15, 1990
Beta-adrenoceptors and the effect of beta-agonists on protein metabolism in ovine primary muscle culturesM E Symonds, J A Roe, C M Heywood, et al.
Communicable Diseases Intelligence (2018)|June 16, 2020
SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018Hazel J Clothier, Jock Lawrie, Georgina Lewis, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition|July 1, 1995
Abundance of endothelial nitric oxide synthase in newborn intrapulmonary arteriesA A Hislop, D R Springall, L D Buttery, et al.
Journal of Molecular Neuroscience : MN|January 1, 1995
Direct evidence that the POU family transcription factor Oct-2 represses the cellular tyrosine hydroxylase gene in neuronal cellsZ Deans, S J Dawson, L Buttery, et al.
Vaccine|January 23, 2024
What would have happened anyway? Population data source considerations when estimating background incident rates of adverse events following immunisation to inform vaccine safetyHazel J Clothier, Aishwarya N Shetty, Yonatan Mesfin, et al.
Pageof 64